Cancers,
Journal Year:
2023,
Volume and Issue:
15(19), P. 4879 - 4879
Published: Oct. 7, 2023
Triple-negative
breast
cancer
(TNBC)
is
an
aggressive
subtype
accounting
for
~10-20%
of
all
human
BC
and
characterized
by
the
absence
estrogen
receptor
(ER),
progesterone
(PR),
epidermal
growth
factor
2
(HER2)
amplification.
Owing
to
its
unique
molecular
profile
limited
targeted
therapies,
TNBC
treatment
poses
significant
challenges.
Unlike
other
subtypes,
lacks
specific
targets,
rendering
endocrine
therapies
HER2-targeted
treatments
ineffective.
The
chemotherapeutic
regimen
predominant
systemic
modality
in
current
clinical
practice.
However,
efficacy
chemotherapy
variable,
with
response
rates
varying
between
a
wide
range
patients,
emerging
resistance
further
adds
difficulties.
Furthermore,
exhibits
higher
mutational
burden
acknowledged
as
most
immunogenic
subtypes.
Consequently,
application
immune
checkpoint
inhibition
has
been
investigated
TNBC,
yielding
promising
outcomes.
Recent
evidence
identified
extracellular
vesicles
(EVs)
important
contributor
context
immunotherapy.
In
view
extraordinary
ability
EVs
transfer
bioactive
molecules,
such
proteins,
lipids,
DNA,
mRNAs,
small
miRNAs,
cells,
are
considered
diagnostic
biomarker
novel
drug
delivery
system
among
prospects
present
review
provides
in-depth
understanding
how
influence
progression,
regulation,
their
contribution
predictive
TNBC.
final
part
focuses
on
recent
key
advances
immunotherapeutic
strategies
better
complex
interplay
developing
EV-based
immunotherapies.
Chemical Communications,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 23, 2024
This
review
explores
the
synthesis,
drug
loading,
and
surface
modifications
of
metal–organic
frameworks
(MOFs),
highlighting
their
role
in
improving
cancer
immunotherapy
paving
way
for
safer
more
effective
treatments.
Medicina,
Journal Year:
2024,
Volume and Issue:
60(1), P. 168 - 168
Published: Jan. 17, 2024
Breast
cancer
is
a
prevalent
malignancy
in
the
present
day,
particularly
affecting
women
as
one
of
most
common
forms
cancer.
A
significant
portion
patients
initially
with
localized
disease,
for
which
curative
treatments
are
pursued.
Conversely,
another
substantial
segment
diagnosed
metastatic
has
worse
prognosis.
Recent
years
have
witnessed
profound
transformation
prognosis
this
latter
group,
primarily
due
to
discovery
various
biomarkers
and
emergence
targeted
therapies.
These
biomarkers,
encompassing
serological,
histological,
genetic
indicators,
demonstrated
their
value
across
multiple
aspects
breast
management.
They
play
crucial
roles
initial
diagnosis,
aiding
detection
relapses
during
follow-up,
guiding
application
treatments,
offering
valuable
insights
prognostic
stratification,
especially
highly
aggressive
tumor
types.
Molecular
markers
now
become
keystone
given
diverse
array
chemotherapy
options
treatment
modalities
available.
signify
transformative
shift
arsenal
therapeutic
against
Their
diagnostic
precision
enables
categorization
tumors
elevated
risks
recurrence,
increased
aggressiveness,
heightened
mortality.
Furthermore,
existence
therapies
tailored
target
specific
molecular
anomalies
triggers
cascade
changes
behavior.
Therefore,
primary
objective
article
offer
comprehensive
review
clinical,
diagnostic,
prognostic,
utility
principal
currently
use,
well
clinical
impact
on
In
doing
so,
our
goal
contribute
more
comprehension
complex
disease
and,
ultimately,
enhance
patient
outcomes
through
precise
effective
strategies.
Expert Opinion on Drug Delivery,
Journal Year:
2024,
Volume and Issue:
21(3), P. 495 - 511
Published: Feb. 24, 2024
Breast
cancer
is
a
global
health
concern
that
demands
attention.
In
our
contribution
to
addressing
this
disease,
study
focuses
on
investigating
wireless
micro-device
for
intratumoral
drug
delivery,
utilizing
electrochemical
actuation.
Microdevices
have
emerged
as
promising
approach
in
field
due
their
ability
enable
controlled
injections
various
applications.
Cellular Molecular and Biomedical Reports,
Journal Year:
2023,
Volume and Issue:
3(4), P. 185 - 196
Published: June 15, 2023
Breast
cancer,
the
most
frequent
disease
in
women
worldwide,
represents
a
significant
public
health
concern
on
global
scale.
cancer
was
type
of
among
Iraqi
2018,
accounting
for
highest
percentage
malignant
tumors
women.
is
set
physiological
and
molecular
heterogeneous
diseases
that
begin
breast.
Advanced
breast
with
distant
organ
metastases
considered
incurable
current
therapies.
Aside
from
new
treatment
improvements,
next
challenge
care
equal
worldwide
access
to
therapeutic
advances.
The
incidence
continues
rise
every
part
world.
Despite
advances
its
identification
treatment,
which
have
resulted
lower
mortality
rates,
it
appears
vital
seek
out
approaches,
predictive
prognostic
indicators.
article
provides
literature
review
carcinoma,
condition
affects
worldwide.
As
result,
should
be
aware
disease's
course,
importance
regular
screenings
early
detection
best
options.
Molecules,
Journal Year:
2023,
Volume and Issue:
28(9), P. 3671 - 3671
Published: April 23, 2023
Magnolin
is
a
naturally
occurring,
multi-bioactive
lignan
molecule
with
inherent
anticancer
effects.
This
study
aims
to
summarize
the
botanical
origins
and
properties
of
magnolin.
For
this,
recent
(as
March
2023)
literature
review
was
conducted
using
various
academic
search
engines,
including
PubMed,
Springer
Link,
Wiley
Online,
Web
Science,
Science
Direct,
Google
Scholar.
All
currently
available
information
about
this
phytochemical
its
role
in
cancer
types
has
been
gathered
investigated.
compound
found
many
different
plants.
It
demonstrated
have
activity
numerous
experimental
models
by
inhibiting
cell
cycle
(G1
G2/M
phase);
inducing
apoptosis;
causing
antiinvasion,
antimetastasis,
antiproliferative
effects
via
modulation
several
pathways.
In
conclusion,
magnolin
showed
robust
against
lines
altering
signaling
pathways
non-
pre-clinical
models,
making
it
promising
plant-derived
chemotherapeutic
option
for
further
clinical
research.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: Nov. 13, 2023
Abstract
Specific
cell
states
in
metazoans
are
established
by
the
symphony
of
gene
expression
programs
that
necessitate
intricate
synergic
interactions
between
transcription
factors
and
co-activators.
Deregulation
these
regulatory
molecules
is
associated
with
state
transitions,
which
turn
accountable
for
diverse
maladies,
including
developmental
disorders,
metabolic
most
significantly,
cancer.
A
decade
back
factors,
key
enablers
disease
development,
were
historically
viewed
as
‘undruggable’;
however,
intervening
years,
a
wealth
literature
validated
they
can
be
targeted
indirectly
through
transcriptional
co-activators,
their
confederates
various
physiological
molecular
processes.
These
along
have
ability
to
initiate
modulate
genes
necessary
normal
functions,
whereby,
deregulation
such
may
foster
tissue-specific
phenotype.
Hence,
it
essential
analyze
how
co-activators
specific
multilateral
processes
coordination
other
factors.
The
proposed
review
attempts
elaborate
an
in-depth
account
involvement
regulation,
context-specific
contributions
pathophysiological
conditions.
This
also
addresses
issue
has
not
been
dealt
comprehensive
manner
hopes
direct
attention
towards
future
research
will
encompass
patient-friendly
therapeutic
strategies,
where
drugs
targeting
enhanced
benefits
reduced
side
effects.
Additional
insights
into
currently
available
interventions
constraints
eventually
reveal
multitudes
advanced
targets
aiming
amelioration
good
patient
prognosis.
The FASEB Journal,
Journal Year:
2024,
Volume and Issue:
38(2)
Published: Jan. 10, 2024
Abstract
Recently,
extracellular
vesicles
(EVs)
have
been
emphasized
in
regulating
the
hypoxic
tumor
microenvironment
of
breast
cancer
(BC),
where
tumor‐associated
fibroblasts
(TAFs)
play
a
significant
role.
In
this
study,
we
describe
possible
molecular
mechanisms
behind
pro‐tumoral
effects
EVs,
secreted
by
hypoxia
(HP)‐induced
TAFs,
on
BC
cell
growth,
metastasis,
and
chemoresistance.
These
are
based
long
noncoding
RNA
H19
(H19)
identified
microarray
analysis.
We
employed
an
silico
approach
to
identify
differentially
expressed
lncRNAs
that
were
associated
with
BC.
Subsequently,
explored
downstream
regulatory
mechanisms.
isolated
EVs
from
TAFs
exposed
HP,
these
denoted
as
HP‐TAF‐EVs
henceforth.
MTT,
transwell,
flow
cytometry,
TUNEL
assays
performed
assess
malignant
phenotypes
cells.
A
paclitaxel
(TAX)‐resistant
line
was
constructed,
xenograft
lung
metastasis
models
established
nude
mice
for
vivo
verification.
Our
observation
revealed
lncRNA
significantly
overexpressed,
whereas
miR‐497
notably
downregulated
HP
induced
activation
stimulated
secretion
EVs.
Coculture
cells
led
increase
TAX
resistance
latter.
upregulated
methylation
delivering
H19,
which
recruited
DNMT1,
thus
lowering
expression
miR‐497.
addition,
H19‐containing
hindered
expression,
enhancing
tumorigenesis
vivo.
study
presents
evidence
contribution
reduction
through
recruitment
turn
promotes
chemoresistance
